TriSalus Life Sciences (TLSI) Equity Average (2021 - 2026)

TriSalus Life Sciences has reported Equity Average for 6 years, with the latest figure at -$10.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 65.06% year-over-year to -$10.5 million; the trailing twelve-month figure through Mar 2026 stood at -$10.5 million (up 65.06% YoY), and the FY2025 full-year result was -$29.9 million, down 12.83% from the prior year.
• Equity Average for Q1 2026 stood at -$10.5 million, up from -$30.3 million in the prior quarter.
• The five-year high for Equity Average was -$9.4 million in Q4 2023, with the low at -$191.5 million in Q2 2023.
• Historically, Equity Average has averaged -$76.3 million across 5 years, with a median of -$30.6 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average slumped 629.81% — and 2023, when it soared 94.33%.
• TriSalus Life Sciences' Equity Average stood at -$165.5 million in 2022, then soared by 94.33% to -$9.4 million in 2023, then plunged by 146.78% to -$23.2 million in 2024, then tumbled by 30.78% to -$30.3 million in 2025, then jumped by 65.25% to -$10.5 million in 2026.
• The last three Equity Average figures came in at -$10.5 million (Q1 2026), -$30.3 million (Q4 2025), and -$23.1 million (Q3 2025), per Business Quant data.